Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | MLNR | O43193 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3583025 | 1.00 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL4596584 | 1.00 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL18411348 | 0.84 | SIGMAR1 (0.53) | SIGMAR1MEN1KMT2A | |
| SCHEMBL14460139 | 0.83 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1KMT2A | |
| SCHEMBL13936121 | 0.83 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1KMT2A | |
| SCHEMBL14401346 | 0.82 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1MLNR | |
| SCHEMBL5058871 | 0.82 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1MLNR | |
| SCHEMBL3165725 | 0.82 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1MLNR | |
| SCHEMBL4678046 | 0.82 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1MLNR | |
| SCHEMBL5060895 | 0.82 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450807-B1 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | VERSI GROUP LLC (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-1450807-A4 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS INC (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7030124-B2 | Method of treating depression with delta receptor agonist compounds | ARDENT PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1450807-A1 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | Ardent Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20030144299-A1 | Method of treating depression with delta receptor agonist compounds | DMK PHARMACEUTICALS CORPORATION | 2003-07-31 | — | — | US | disclosed |
| WO-2003037342-A1 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144299-A1 | Method of treating depression with delta receptor agonist compounds | CHRND, CHRNE, CHRNA3 | SIGMAR1 213/4885ALDH1A1 2617/4885SMN1; SMN2 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.